Loss of Midbrain Dopamine Neurons and Altered Apomorphine EEG Effects in the 5xFAD Mouse Model of Alzheimer's Disease.

Cognitive malfunction, synaptic dysfunction, and disconnections in neural networks are core deficits in Alzheimer's disease (AD). 5xFAD mice, a transgenic model of AD, are characterized by an enhanced level of amyloid-β and abnormal neurotransmission. The dopaminergic (DA) system has been shown to be involved in amyloid-β transformations and neuronal plasticity; however, its role in functional network changes in familial AD still remains unclear. In 5xFAD and non-transgenic freely moving mice, electroencephalograms (EEGs) were simultaneously recorded from the secondary motor cortex (MC), superficial layers of the hippocampal CA1 area (HPC), substantia nigra (SN), and ventral tegmental area (VTA). EEGs and their frequency spectra were analyzed before and after systemic injection of a DA receptor agonist, apomorphine (APO). In the baseline EEG from MC and HPC of 5xFAD mice, delta and alpha oscillations were enhanced and beta activity was attenuated, compared to control mice. In VTA and SN of 5xFAD mice, delta-theta activity was decreased and beta oscillations dominated. In control mice, APO suppressed delta activity in VTA to a higher extent than in MC, whereas in 5xFAD mice, this difference was eliminated due to attenuation of the delta suppression in VTA. APO increased beta activity in MC of mice from both groups while significant beta suppression was observed in VTA of 5xFAD mice. These mice were characterized by significant decrease of tyrosine hydroxylase immunopositive cells in both VTA and SN and of DA transporter in MC and hippocampal dentate gyrus. We suggest that the EEG modifications observed in 5xFAD mice are associated with alterations in dopaminergic transmission, resulting in adaptive changes in the cerebral networks in the course of familial AD development.

[1]  V. Vorobyov,et al.  Dopaminergic mediation in the brain aging and neurodegenerative diseases: a role of senescent cells , 2018, Neural regeneration research.

[2]  G. Pei,et al.  Dopamine D2 receptor and β-arrestin 2 mediate Amyloid-β elevation induced by anti-parkinson’s disease drugs, levodopa and piribedil, in neuronal cells , 2017, PloS one.

[3]  G. Miller,et al.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease , 2017, The European journal of neuroscience.

[4]  L. Mucke,et al.  Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.

[5]  M. T. Shipley,et al.  Subsecond Regulation of Synaptically Released Dopamine by COMT in the Olfactory Bulb , 2016, The Journal of Neuroscience.

[6]  B. Liss,et al.  Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease , 2016, Journal of neurochemistry.

[7]  T. Kiss,et al.  Neuronal network activity in the hippocampus of tau transgenic (Tg4510) mice , 2016, Neurobiology of Aging.

[8]  D. Tampellini,et al.  Synaptic activity and Alzheimer's disease: a critical update , 2015, Front. Neurosci..

[9]  N. Axmacher,et al.  Neuronal Network Oscillations in Neurodegenerative Diseases , 2015, NeuroMolecular Medicine.

[10]  Zayd M. Khaliq,et al.  Tonic Firing Rate Controls Dendritic Ca2+ Signaling and Synaptic Gain in Substantia Nigra Dopamine Neurons , 2015, The Journal of Neuroscience.

[11]  A. Papazoglou,et al.  Altered Theta Oscillations and Aberrant Cortical Excitatory Activity in the 5XFAD Model of Alzheimer's Disease , 2015, Neural plasticity.

[12]  A. Papazoglou,et al.  Limited Effects of an eIF2α S51A Allele on Neurological Impairments in the 5xFAD Mouse Model of Alzheimer's Disease , 2015, Neural plasticity.

[13]  C. Paladini,et al.  Generating bursts (and pauses) in the dopamine midbrain neurons , 2014, Neuroscience.

[14]  K. Reymann,et al.  Behavioral and EEG changes in male 5xFAD mice , 2014, Physiology & Behavior.

[15]  G. Ellis‐Davies,et al.  Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice , 2013, Neuroscience.

[16]  Vladimir Litvak,et al.  Synchronized neural oscillations and the pathophysiology of Parkinson's disease. , 2013, Current opinion in neurology.

[17]  Robert W Gereau,et al.  Dopamine-Dependent Compensation Maintains Motor Behavior in Mice with Developmental Ablation of Dopaminergic Neurons , 2013, The Journal of Neuroscience.

[18]  J. Dalley,et al.  Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra , 2013, Experimental Neurology.

[19]  F. Roman,et al.  Area-Specific Alterations of Synaptic Plasticity in the 5XFAD Mouse Model of Alzheimer’s Disease: Dissociation between Somatosensory Cortex and Hippocampus , 2013, PloS one.

[20]  Jesse Jackson,et al.  Alterations in hippocampal network oscillations and theta–gamma coupling arise before Aβ overproduction in a mouse model of Alzheimer's disease , 2013, The European journal of neuroscience.

[21]  J. Delgado-García,et al.  Accelerated aging of the GABAergic septohippocampal pathway and decreased hippocampal rhythms in a mouse model of Alzheimer's disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[23]  Liam Scott,et al.  Age-dependent disruption in hippocampal theta oscillation in amyloid-β overproducing transgenic mice , 2012, Neurobiology of Aging.

[24]  C. Koch,et al.  The origin of extracellular fields and currents — EEG, ECoG, LFP and spikes , 2012, Nature Reviews Neuroscience.

[25]  M. Blurton-Jones,et al.  Examining the mechanisms that link β-amyloid and α-synuclein pathologies , 2012, Alzheimer's Research & Therapy.

[26]  Oliver Wirths,et al.  Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease , 2012, Neurobiology of Aging.

[27]  L. Mucke,et al.  Ablation of Cellular Prion Protein Does Not Ameliorate Abnormal Neural Network Activity or Cognitive Dysfunction in the J20 Line of Human Amyloid Precursor Protein Transgenic Mice , 2011, The Journal of Neuroscience.

[28]  G. Bernardi,et al.  Altered dopamine modulation of LTD-like plasticity in Alzheimer’s disease patients , 2011, Clinical Neurophysiology.

[29]  T. Tabira,et al.  Apomorphine treatment in Alzheimer mice promoting amyloid‐β degradation , 2011, Annals of neurology.

[30]  M. Khamassi,et al.  Coherent Theta Oscillations and Reorganization of Spike Timing in the Hippocampal- Prefrontal Network upon Learning , 2010, Neuron.

[31]  F. Sengpiel,et al.  Apomorphine-induced differences in cortical and striatal EEG and their glutamatergic mediation in 6-hydroxydopamine-treated rats , 2008, Experimental Brain Research.

[32]  R. Kostrzewa,et al.  Dopamine receptor supersensitivity: Development, mechanisms, presentation, and clinical applicability , 2008, Neurotoxicity Research.

[33]  S. J. Shammah-Lagnado,et al.  Organization of ventral tegmental area projections to the ventral tegmental area–nigral complex in the rat , 2008, Neuroscience.

[34]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[35]  T. Sotnikova,et al.  Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. , 2006, CNS & neurological disorders drug targets.

[36]  E. John,et al.  Decreased EEG synchronization in Alzheimer’s disease and mild cognitive impairment , 2005, Neurobiology of Aging.

[37]  R. Davidson What does the prefrontal cortex “do” in affect: perspectives on frontal EEG asymmetry research , 2004, Biological Psychology.

[38]  David M. Smith,et al.  Firing properties of dopamine neurons in freely moving dopamine-deficient mice: effects of dopamine receptor activation and anesthesia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Manuel Buttini,et al.  Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. , 2004, The American journal of pathology.

[40]  I Tobler,et al.  The dynamics of spindles and EEG slow-wave activity in NREM sleep in mice. , 2004, Archives italiennes de biologie.

[41]  Charles Duyckaerts,et al.  Dopamine depletion impairs precursor cell proliferation in Parkinson disease , 2004, Nature Neuroscience.

[42]  H. Möller,et al.  Core biological marker candidates of Alzheimer’s disease – perspectives for diagnosis, prediction of outcome and reflection of biological activity , 2004, Journal of Neural Transmission.

[43]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[44]  H. Tanila,et al.  Alteration of cortical EEG in mice carrying mutated human APP transgene , 2002, Brain Research.

[45]  H. Dringenberg,et al.  Alzheimer's disease: more than a ‘cholinergic disorder' — evidence that cholinergic–monoaminergic interactions contribute to EEG slowing and dementia , 2000, Behavioural Brain Research.

[46]  Charles R. Yang,et al.  Medial prefrontal cortical output neurons to the ventral tegmental area (VTA) and their responses to burst‐patterned stimulation of the VTA: Neuroanatomical and in vivo electrophysiological analyses , 1999, Synapse.

[47]  M. Spedding,et al.  Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission , 1999, British journal of pharmacology.

[48]  V. V. Vorob’ev,et al.  Analysis of electroencephalograms using a modified amplitude-interval algorithm , 1999, Neuroscience and Behavioral Physiology.

[49]  F Lepore,et al.  Interhemispheric disconnection syndrome in Alzheimer's disease. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  C. Gerfen,et al.  Basic Neuroanatomical Methods , 1997, Current protocols in neuroscience.

[51]  E. Ongini,et al.  Sedation and sleep induced by high doses of apomorphine after blockade of D-1 receptors by SCH 23390. , 1985, European journal of pharmacology.

[52]  U. Ungerstedt,et al.  Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis. , 1984, European journal of pharmacology.

[53]  F. Sengpiel,et al.  Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[54]  Sonja Seeger-Armbruster,et al.  Short- and long-term unilateral 6-hydroxydopamine lesions in rats show different changes in characteristics of spontaneous firing of substantia nigra pars reticulata neurons , 2012, Experimental Brain Research.

[55]  A. Grace,et al.  Cortico-Basal Ganglia Reward Network: Microcircuitry , 2010, Neuropsychopharmacology.

[56]  P. Overton,et al.  Antagonism of NMDA receptors but not AMPA/kainate receptors blocks bursting in dopaminergic neurons induced by electrical stimulation of the prefrontal cortex , 2005, Journal of Neural Transmission.